2018/2019 Bladder Cancer Canada Grant Recipients
Twenty-five percent of patients with bladder cancer are diagnosed with muscle-invasive disease. These patients usually receive chemotherapy followed by surgery to remove the bladder. Up to 60% of tumours, however, do not respond to chemotherapy. This study aims to measure the abnormal biological pathways in bladder tumour tissue at the RNA and protein levels, and to identify the pathways responsible for resistance to chemotherapy. This approach will allow Dr. Black’s research team to identify mechanisms of resistance to chemotherapy and, in the future, test drugs that block the identified resistance pathways. If successful, this project will open the door to novel therapies to overcome chemo-resistance.
Pictured below (L-R): Gregg Morin, PhD (Head of Proteomics, BC Cancer Genome Sciences Centre); Lead Investigator – Peter Black, MD FRCSC (Professor, University of British Columbia); Josa Batista da Costa, MD (post-doc); Kenichiro Ikeda, MD PhD (post-doc)